title: The novel squamosamide derivative FLZ protects against 6-hydroxydopamine-induced apoptosis through inhibition of related signal transduction in SH-SY5Y cells.
abstract: Compound FLZ is a synthetic novel derivative of squamosamide. Previous pharmacological study found that FLZ improved the abnormal behavior and the decrease of dopamine content in striatum in 6-hydroxydopamine (6-OHDA) model mice. 6-OHDA can cause Parkinsonism in experimental animals. The purpose of this paper was to study the protective action of FLZ against 6-OHDA-induced apoptosis and alternations of related signal transduction. The results indicated that FLZ at concentrations of 0.1 microM and 1 microM prevented 6-OHDA-induced apoptosis of SH-SY5Y cells, and inhibited the increase of cytochrome c and Apoptosis-inducing factor (AIF) release and activation of Caspase 3 and NF-kappaB. The results suggested that FLZ has potential neuroprotective effect on 6-OHDA-induced apoptosis of SH-SY5Y cells through regulating related signal-transduction.
authors.affiliation: Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Zhang
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Zhang
authors.forename: Geng-Tao
authors.initials: GT
authors.lastname: Liu
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D051033:Apoptosis Inducing Factor / Q000187:drug effects* / Q000378:metabolism; D044482:Benzeneacetamides / Q000008:administration & dosage / Q000494:pharmacology*; D053148:Caspase 3 / Q000187:drug effects / Q000378:metabolism; D002460:Cell Line; D002470:Cell Survival; D045304:Cytochromes c / Q000187:drug effects / Q000378:metabolism; D016503:Drug Delivery Systems; D008954:Models, Biological; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D016627:Oxidopamine / Q000633:toxicity; D010300:Parkinson Disease / Q000188:drug therapy; D010636:Phenols / Q000008:administration & dosage / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D051033:Apoptosis Inducing Factor; D044482:Benzeneacetamides; D016328:NF-kappa B; D018696:Neuroprotective Agents; D010636:Phenols; C084439:squamosamide; D016627:Oxidopamine; D045304:Cytochromes c; D053148:Caspase 3